Show results for
Refine by
Drug Platform Suppliers Serving Libya
44 companies found
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of ...
based inStanmore, UNITED KINGDOM
Acellera’s mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. In order to fulfill this vision, we work with our customers by becoming a key technology partner, boosting their ...
based inBerwyn, PENNSYLVANIA (USA)
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate. Our transforming ...
based inEstuary Banks, UNITED KINGDOM
For over 35 years, Powder Systems Limited (PSL) has been at the forefront of designing and engineering advanced technology to support process development. We are a globally recognised, award-winning business with expertise in pharmaceutical and ...
The MSR™ MicroSphere Refiner is a cGMP piece of equipment that allows drug developers and manufacturers to complete a wide range of aseptic processes with their microspheres at various scales. It is a one-of-its-kind solution has been ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties. TLC has proprietary solution for pharmaceutical product development called LipAD®. LipAD® ...
based inColumbus, OHIO (USA)
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and ...
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
Hybridoma technology features the effective usage of innate functions of both immune and cancer cells to generate monoclonal antibodies (mAbs). The resulting hybridoma cell lines are produced to combat specific antigens of interest. Such technology ...
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
based inBeach Drive, UNITED KINGDOM
Oval aims to bring truly patient-centric autoinjector platforms to market. Founded in 2009 by Matthew Young, Oval takes a different approach, designing from the outside in, ensuring that all patient needs are met. Our team has a wide range of ...
Oval’s philosophy is to design platforms to be customisable for specific patient needs. Going deeper than the immediate cognitive and physical need when delivering a drug, we look at each patient group’s ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Many intravenously delivered Active Pharmaceutical Ingredients (APIs) are insoluble or poorly soluble in water. This can be a major hurdle in pharmaceutical development and may cause promising drugs to fail during the development process and may ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
Once a target is identified the various effects of the drug can be measured. This involves all read-outs we use during the biomarker validation but instead of looking at the effect of various candidates we focus on one component. As the tumor ...
based inCambridge, MASSACHUSETTS (USA)
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research ...
Analyze and prioritize based on the frequency, severity, and potential impact of signals to deliver the highest level of drug safety. ...
based inBalerna, SWITZERLAND
APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is ...
based inSonceboz-Sombeval, SWITZERLAND
SONCEBOZ SA is a company which has earned a global reputation for its mechatronic drive systems designed to meet the specific needs of its customers. We create, develop and produce high quality mechatronic systems. Designed for positioning, flow ...
Manual Reconstitution of lyophilized drug formulations is a complex procedure and challenging for patients and caregivers alike. The ARI automatically facilitates the mixing of diluent and lyophilized drug in a easy-to-use fashion without the need ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
based inGoettingen, GERMANY
We provide the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all ...
Human serum albumin (HSA) is the most abundant protein in human blood, constituting approximately half of the total plasma proteins. Albumin is responsible for maintaining oncotic pressure, plasma pH and distribution of a variety of molecules, ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
Exploiting RNA dynamics: RNAs rapidly exchange between a vast array of distinct 3D conformations, each revealing potentially novel binding surfaces. These dynamics are critical to understanding RNA function and fully exploiting its untapped ...
based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic ...
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
based inOttawa, SWITZERLAND
Orion Biotechnology is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. The company is advancing a diversified ...
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the ...